JP2019513780A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513780A5
JP2019513780A5 JP2018553953A JP2018553953A JP2019513780A5 JP 2019513780 A5 JP2019513780 A5 JP 2019513780A5 JP 2018553953 A JP2018553953 A JP 2018553953A JP 2018553953 A JP2018553953 A JP 2018553953A JP 2019513780 A5 JP2019513780 A5 JP 2019513780A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
hearing loss
ear
platinum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018553953A
Other languages
English (en)
Japanese (ja)
Other versions
JP7158723B2 (ja
JP2019513780A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/059058 external-priority patent/WO2017178645A1/en
Publication of JP2019513780A publication Critical patent/JP2019513780A/ja
Publication of JP2019513780A5 publication Critical patent/JP2019513780A5/ja
Application granted granted Critical
Publication of JP7158723B2 publication Critical patent/JP7158723B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018553953A 2016-04-14 2017-04-14 耳疾患の処置における使用のための(+)-アザセトロン Active JP7158723B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662322690P 2016-04-14 2016-04-14
US62/322,690 2016-04-14
EP16180192.3 2016-07-19
EP16180192 2016-07-19
PCT/EP2017/059058 WO2017178645A1 (en) 2016-04-14 2017-04-14 (+)-azasetron for use in the treatment of ear disorders

Publications (3)

Publication Number Publication Date
JP2019513780A JP2019513780A (ja) 2019-05-30
JP2019513780A5 true JP2019513780A5 (https=) 2021-08-12
JP7158723B2 JP7158723B2 (ja) 2022-10-24

Family

ID=65588799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018553953A Active JP7158723B2 (ja) 2016-04-14 2017-04-14 耳疾患の処置における使用のための(+)-アザセトロン

Country Status (18)

Country Link
US (2) US11612605B2 (https=)
EP (1) EP4335508A3 (https=)
JP (1) JP7158723B2 (https=)
CN (1) CN109310698B (https=)
AU (1) AU2023202897B2 (https=)
CL (1) CL2018002930A1 (https=)
DK (1) DK3442537T3 (https=)
ES (1) ES2975016T3 (https=)
FI (1) FI3442537T3 (https=)
HR (1) HRP20240453T1 (https=)
HU (1) HUE066000T2 (https=)
IL (1) IL262305B (https=)
MX (1) MX384045B (https=)
NZ (1) NZ747201A (https=)
PL (1) PL3442537T3 (https=)
RS (1) RS65379B1 (https=)
SI (1) SI3442537T1 (https=)
ZA (1) ZA201806894B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2882602T3 (es) * 2015-05-18 2021-12-02 Sensorion Azasetrón para usar en el tratamiento de la pérdida auditiva

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US5360800A (en) 1987-09-03 1994-11-01 Glaxo Group Limited Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
CA1304082C (en) 1987-10-22 1992-06-23 Tetsuya Tahara Benzoxazine compounds and pharmaceutical use thereof
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB0009914D0 (en) 2000-04-20 2000-06-07 Metris Therapeutics Limited Device
GB0104554D0 (en) 2001-02-23 2001-04-11 Glaxo Group Ltd New uses
US20030044356A1 (en) 2001-04-20 2003-03-06 Jin Auh Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one)
US20030229333A1 (en) * 2002-02-22 2003-12-11 Control Delivery Systems, Inc. Methods for treating otic disorders
GB0213869D0 (en) 2002-06-17 2002-07-31 Arakis Ltd The treatment of pain
NZ541009A (en) 2003-01-13 2007-09-28 Dynogen Pharmaceuticals Inc Method of treating nausea, vomiting, retching or any combination thereof
TWI355936B (en) 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US20040204466A1 (en) 2003-04-14 2004-10-14 Orchid Chemicals And Pharmaceuticals Ltd. Treatment of bronchial asthma using 5-HT3 receptor antagonists
US20070265329A1 (en) 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
US20100016218A1 (en) 2008-07-14 2010-01-21 Otonomy, Inc. Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
EP2253316B1 (en) * 2009-05-20 2013-08-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin 5-HT3 receptor antagonists for use in the treatment or prevention of an inner ear pathology with vestibular deficits
CN102458400B (zh) 2009-05-20 2014-10-08 国立健康与医学研究所 用于治疗病灶性前庭功能障碍的血清素5-ht3受体拮抗剂
CN101786963B (zh) 2010-03-03 2013-05-08 山东众诚药业股份有限公司 阿扎司琼中间体的合成方法
JP2015511242A (ja) 2012-02-23 2015-04-16 インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラリシェルシェ メディカル) 病変性前庭障害の治療に使用するカルシニューリン阻害剤
EP2872128B1 (en) 2012-07-16 2020-02-19 Cornell University Nicotinamide riboside to treat hearing loss
BR112016002205A2 (pt) * 2013-07-31 2017-08-01 Bluepharma Ind Farmaceutica S A filmes orodispersíveis
CN104557906A (zh) 2015-01-21 2015-04-29 扬子江药业集团四川海蓉药业有限公司 一种盐酸阿扎司琼的制备方法
ES2882602T3 (es) * 2015-05-18 2021-12-02 Sensorion Azasetrón para usar en el tratamiento de la pérdida auditiva

Similar Documents

Publication Publication Date Title
RU2469726C2 (ru) Композиции с контролируемым высвобождением на основе кортикостероидов для лечения ушных болезней
RU2499592C2 (ru) Фармацевтическая композиция для лечения ушных заболеваний
JP2019524657A5 (https=)
ES2909395T3 (es) Fomento del crecimiento del cabello y tratamiento de la pérdida del cabello o caída excesiva del cabello
JP5612473B2 (ja) 難聴を処置又は予防するための1−アミノ−アルキルシクロヘキサン誘導体
EP4523752A3 (en) Film formulations containing dexmedetomidine and methods of producing them
JP2015091822A5 (https=)
JP2015212268A5 (https=)
JP2015532296A5 (https=)
JP2014065696A5 (https=)
JP2020530831A5 (https=)
JP2021152060A (ja) アカンプロセートおよびd−サイクロセリンを使用する組み合わせ療法
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
JP2015516988A5 (https=)
JP2019518022A5 (https=)
RU2019138166A (ru) Средство для профилактики или лечения атрофии головного мозга
JP2016530238A5 (https=)
US11690830B2 (en) Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
JP2019513780A5 (https=)
KR102429935B1 (ko) 귀 장애의 치료에 사용하기 위한 (+)-아자세트론
IL272834B2 (en) Amantadine compositions, preparations thereof, and methods of use
FI3442537T3 (fi) (+)-Atsasetroni käytettäväksi korvaan liittyvien häiriöiden hoitoon
JP2015515971A5 (https=)
JP2017052778A5 (https=)
TH1801006398A (th) (+)-อะซาชีตรอนสำหรับการใช้ในการรักษาความผิดปกติของหู